In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.
|Webcasts|June 17, 2020
Clinical Trials: Navigating Disruption to Thriving
Hear from R&D experts, Bazgha Qutab and Sharma Ramanathan, on key trends shaping clinical trials and how clinical ops leaders can not only navigate through disruption, but thrive, in order to bring new therapies to patients faster. Live Q&A to follow. Live: Wednesday, Jun. 17, 2020 at 10am EDT | 9am CDT | 3pm BST | 4pm CEST On demand available after airing until Jun. 17, 2021. Register free
Register free:
Event Overview:
Many patients don’t have time to lose when it comes to receiving potentially life-saving treatments, especially during COVID-19 where resources are scarce and operations are shifting to more virtual settings. It is now more critical than ever to revitalize clinical trials by taking a patient-centric approach and implement mitigation strategies focused on rapid analytics. During this webcast, we’ll discuss key trends, explore new ways to bring potential therapies to patients faster by utilizing the right data and digital tools, and provide guidance on mitigating disruption (patient shortage, supply shortages, navigating pandemics and more).
Key Learning Objectives:
- Understand the impact of disruptions on clinical trials and patients in light of COVID-19
- Gain insight into key mitigation strategies companies are taking and ZS’s point of view on four critical steps required
- Learn how to pivot in this environment through harnessing data and advanced analytics, using a case study example
- Develop a communication strategy focused on patients to accelerate progress in virtual settings
Speakers: Bazgha Qutab, Associate Principal, ZS
Sharma Ramanathan, Business Process Manager, ZS
Time and date: Wednesday, Jun. 17, 2020 at 10am EDT | 9am CDT | 3pm BST | 4pm CEST
On demand available after airing until Jun. 17, 2021.
Sponsor: ZS
Register free:
Related to this article
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal
In today’s ACT Brief, we examine why community research needs lasting financing and infrastructure, how electronic outcome tools can strengthen neuroscience endpoints, and how Teva is licensing two biosimilars from Samsung Bioepis.
Neuroscience trials struggle to show benefit because symptoms are subjective and variable, and eCOA strengthens dossiers by standardizing ClinRO administration, capturing outcomes in real time to reduce recall bias, and adding patient and caregiver perspectives that clinician scales miss.
Community participation gaps look less like a question of patient willingness and more like a financing and infrastructure problem that no single bill has yet solved.
In today’s ACT Brief, we examine what changes when AI is embedded across clinical operations, why faster trial data isn’t yet producing faster decisions, and how FDA granted accelerated approval to a therapy for a rare airway disease.
Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
Trending on Applied Clinical Trials Online
1
Comparing OpenAI and Mistral on Clinical Trial Matching
2
Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health
3
From Complexity to Endpoint Meaningfulness: Addressing Key Neuroscience Trial Challenges with eCOA
4
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
5